Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.84
+0.40003.22%
Post-market: 13.020.1800+1.40%19:50 EDT
Volume:3.35M
Turnover:43.22M
Market Cap:1.80B
PE:-3.84
High:13.13
Open:12.65
Low:12.65
Close:12.44
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.92
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.47
PE(LYR):-3.37

Loading ...

Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target

TIPRANKS
·
Aug 15

Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees

Reuters
·
Aug 08

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)

TIPRANKS
·
Aug 07

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

Solid Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Reuters
·
Aug 07

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating

MT Newswires Live
·
Aug 06

Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Loss $0.80 a Share, vs. FactSet Est of $0.80 Loss

MT Newswires Live
·
Aug 06

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million

Reuters
·
Aug 06

Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate

Benzinga Earnings
·
Aug 06

Intellia Therapeutics Q2 Net Income USD -106.634 Million

Reuters
·
Aug 06

Intellia Therapeutics Q2 Basic EPS USD -0.8

THOMSON REUTERS
·
Aug 06

Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales But Fairer On Broader Checks

Simply Wall St.
·
Aug 06

Intellia Therapeutics Schedules Conference Call to Discuss Q2 2026 Results and Business Updates

Reuters
·
Jul 30

Intellia Therapeutics Cut to Underperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Jul 16